Lakefront Biotherapeutics Reports Half-Year 2026 Financial Results and Provides Business Update

The acquisition of Ouro Medicines by Gilead Sciences has been successfully concluded. This collaboration aims to further develop a groundbreaking T-cell engager, potentially the first and most effective of its kind.